ICONSIAM and TAT to Host the “Amazing Thailand Countdown 2025” to Position Thailand as the World’s Top Countdown Destination

Listen to this story

ICONSIAM, in collaboration with the Tourism Authority of Thailand (TAT) and key partners, is set to host the “Amazing Thailand Countdown 2025,” an event expected to draw an audience of around 30 million people worldwide and highlight Thailand as a leading global countdown destination.

Supoj Chaiwatsirikul, Managing Director of ICONSIAM, stated that ICONSIAM, alongside public and private sector partners—including TAT, Bangkok Metropolitan Administration (BMA), Thai Chamber of Commerce, Charoen Pokphand Group, Charoen Pokphand Foods, CP All, True Corporation, CP Axtra, Kasikorn Bank, Thai Honda, Magnolia Quality Development Corporation, and community partners along the Chao Phraya River—will host the event from December 29 to 31, 2024. International and Thai artists, including world-renowned star Lalisa “Lisa” Manoban, will participate in the celebrations.

“The Amazing Thailand Countdown 2025 promises to be Thailand’s most impressive year-end event, with highlights such as the longest eco-friendly fireworks display, stretching over 1,400 meters along the Chao Phraya River. In addition, there will be live performances by both international and Thai artists across the three days and nights, drawing over 30 million viewers both in person and through live broadcasts worldwide,” he said.

Thapanee Kiatphaibool, Governor of TAT, noted that Thailand’s tourist numbers for this year have already reached 30 million, with a target of 35 million by year’s end. She emphasized that the “Amazing Thailand Countdown 2025” will be one of the country’s key attractions.

“Last year, the countdown event was ranked among the world’s top five destinations, and we aim to further elevate its status as the world’s leading countdown celebration,” she said.

COVID-19

Ivermectin not effective in treating Covid-19, joint Mahidol-Oxford study shows

Ivermectin is not shown to be effective against Covid-19 in clinical trials according to the findings of a joint...

Latest article